

Gyrolab® Assays

Remicade® (infliximab) ADA Assay

INTRODUCTION


Remicade (infliximab) is an anti-inflammatory biopharmaceutical that belongs to the group of TNF- α (tumor necrosis factor-alpha) inhibitors. Remicade (infliximab) is a chimeric monoclonal antibody composed of 75% human constant regions and 25% murine variable regions.

Anti-drug antibodies (ADA) can be generated by patients when biopharmaceuticals are administered. The presence of ADA can inhibit biopharmaceuticals binding the target, impact the PK profile, and affect safety and efficacy. Detection and characterization of ADA is an integral part of biopharmaceutical drug development.

We have developed a homogenous bridging Gyrolab ADA assay with automated acid dissociation to determine levels of anti-Remicade antibodies in human serum samples. An MRD of 10 in Rexpip® ADA gives a specific and drug tolerant assay. Use of this protocol on Gyrolab systems will reduce time to market and increase productivity while maintaining quality requirements.

ASSAY DESIGN

The assay was set up as a homogenous bridging assay following acid dissociation using 0.5 M Glycin-HCl, pH 2.6, with biotinylated Remicade as a capture molecule and Remicade labeled with Alexa Fluor® 647 as a detection molecule. The positive control used for this assay was a human anti-idiotypic mAb from a commercial source.



ASSAY PERFORMANCE

Assay Sensitivity

The assay sensitivity was estimated from the screening cut point as 7.68 ng/mL of positive control antibody, see Figure 1. Due to the qualitative nature of ADA assays the assay sensitivity is not an absolute concentration of anti-drug antibody, and may be different in a clinical setting. Use of a surrogate positive control is, however, industry practice and accepted by regulatory agencies.




Figure 1. Positive control titration in Rexpip ADA with 10% serum. Screening cutpoint at 0.139 RU. Concentrations in neat serum.

Assay screening cut point

A floating cut point with 5% false-positive rate was estimated from 54 treatment naïve healthy mixed gender individuals, analyzed once each across three independent runs. The normalized responses (Mean Individual RU / Assay Mean NC RU) of the individuals were found to be normally distributed (Shapiro-Wilkes $\alpha=0.05$) and was therefore not log transformed. No values were found to be outliers by Grubbs test. This would not constitute a validated cut point assessment but was estimated from the principles outlined in Shankar et al. (Recommendations for the Validation of Immunoassays Used for Detection of Host Antibodies Against Biotechnology Products. Journal of Pharmaceutical and Biomedical Analysis 2008;48:1267-1281). The average responses for individuals and positive controls are shown in Figure 2. The floating cut point was set as Mean NC RU + 0.019.




Figure 2 Average of duplicate responses (RU) from Negative Control (NC) Positive Controls (PC) at 10 ng/mL and individual human serum samples (Individual 01 – 54) in REXXIP ADA, for a final concentration of 10% human serum. Concentrations of PC in neat serum.

Screening assay precision

The assay precision across three runs for the positive control at 10 ng/mL was 9.1% and precision for the pooled negative control over the same three runs was 11.7%, as seen in Table 1.

Table 1 Precision assessment of the screening assay over three runs

Parameter	Negative Control (Pooled human serum)	Positive Control (10 ng/mL)
Average response	0.131 RU	0.212 RU
Intra-assay precision	≤19.4%	≤11.8%
Inter-assay precision	11.7%	9.1%

Confirmatory assay

Mixed gender individuals were analyzed in three runs following a 1-in-10 MRD using assay diluent with 200 µg/mL Remicade and without Remicade to determine the level of inhibition equivalent to a 1% false positive rate. The confirmatory cut point was determined from this set of individuals as 26.5% inhibition in the presence of Rexpix ADA with 200 µg/mL Remicade. None of the individuals that screened positive were confirmed positive.

Drug tolerance

Drug tolerance was assessed by titrating concentrations of Remicade in the presence of 100 ng/mL ADA positive control in pooled human serum. At 100 ng/mL of positive control drug tolerance was set at 160 µg/mL of Remicade as this is the concentration above which the positive control response falls below the screening cut point, see Figure 3. A plateau in inhibition of 100 ng/mL of ADA positive control was achieved at 320 µg/mL of Remicade, equivalent to average response of assay blank at 0.115 RU; inhibition results are shown in Table 2. The estimated trough level of Remicade in human serum is ≤ 5 µg/mL.

Table 2 Drug tolerance assessment in the presence of 100 ng/mL positive control

Remicade Conc. (µg/mL)	100 ng/mL Positive Control	
	Average response (RU)	% Inhibition
0	0.630	N/A
10	0.467	31.5
20	0.389	46.8
40	0.313	61.5
80	0.213	81.1
160	0.153	92.8
320	0.113	100.5
640	0.114	100.3
1 280	0.110	101.0




Figure 3 Titration of Remicade in Rexpix ADA with 10% serum and 100 ng/mL of positive control. Concentrations in neat serum.

MATERIALS AND METHODS

The assay was developed on a Gyrolab xP system using Gyrolab Mixing CD 96. The assay was set up using a 1-step Gyrolab method with two wash solutions (Mixing96-1W-003-A) and a 5% PMT setting. The assay buffer was Rexpix® ADA with 10% human serum, the confirmatory assay buffer was Rexpix ADA with 10% human serum and 200 µg/mL of Remicade. The acid dissociation step was performed using 0.5 M Glycin-HCl, pH 2.6. A bridging assay format was used with equal concentrations of capture and detection reagents in 1 M Tris-HCl pH 8.

The capture reagent was the chimeric monoclonal antibody infliximab (Remicade) from Jansen Biologics. 100 µg of Remicade (1 mg/mL in PBS) was biotinylated according to the Gyrolab biotinylation protocol (Gyrolab User Guide), with a 1:12 challenge ratio of biotin. Capture reagent was used in mastermix at a concentration of 3 µg/mL in Rexpix ADA.

The detection reagent was the chimeric monoclonal antibody infliximab (Remicade) from Jansen Biologics. 100 µg of Remicade (1 mg/mL in PBS) was labeled with one vial of Alexa Fluor® 647 according to the Gyrolab standard protocol (Gyrolab User Guide). The detection reagent was used in mastermix at a concentration of 3 µg/mL in Rexpix ADA.

The positive control used was a human anti-infliximab monoclonal antibody, clone AbD17841_hlgG1, sourced from Bio-Rad (HCA213), diluted in REXXIP ADA with 10% human serum.

Summary table

Capture	Biotin labeled infliximab (Remicade, Jansen Biologics), 12:1 molar challenge ratio
Detection	Alexa Fluor 647 labeled infliximab (Remicade, Jansen Biologics)
Mastermix	3 µg/mL detection reagent and 3 µg/mL capture reagent in 1 M Tris-HCL pH 8
Acidic Buffer	0.5 M Glycin-HCl, pH 2.6
Analyte	Human anti-infliximab monoclonal antibody (HCA213; Bio-Rad) in REXXIP ADA with 10% human serum
CD-type	Gyrolab Mixing CD 96
Method	Mixing96-1W-003-A
Wash buffer for needles	Wash buffer 1: PBS-T Wash buffer 2: Gyrolab Wash Buffer pH 11
PMT-setting	5%
Negative Control inter assay precision	11.7%
Suggested Positive Control concentration	PC: 10 ng/mL**
Confirmatory drug concentration in REXXIP ADA with 10% human serum	200 µg/mL
Assay sensitivity	7.68 ng/mL*
Drug tolerance	160 µg/mL*
Screening Cut point	0.019 + Mean NC RU*
Confirmatory Cut point	26.5% inhibition*

* These values are dependent on the pool and individuals used in the assay validation.

** Recommended Positive Control concentration updated following sensitivity assessment.

Recommendations

When developing this assay for a specific drug development purpose, it is important to perform in-house screening of matrices and determine population screening cutpoint correction factor. Parameters, such as sensitivity and positive control concentrations should be validated in-house. Data given in this document should only be considered as guidance. Additional details on recommendations for optimizing an ADA method on the Gyrolab system can be found via the Gyrolab User Zone.

For additional support contact your local Field Application Support

Gyrolab and REXXIP are registered trademarks and Gyros, Gyrolab xPlore, Gyroplex, Bioaffy and Gyros logo are trademarks of Gyros Protein Technologies Group. All other trademarks are the property of their respective owners. Products and technologies from Gyros Protein Technologies are covered by one or more patents and/or proprietary intellectual property rights. All infringements are prohibited and will be prosecuted. Please contact Gyros Protein Technologies AB for further details. Products are for research use only. Not for use in diagnostic procedures. © Gyros Protein Technologies AB 2021. D0038178/B.